Digreen

Quick links to important sections

Digreen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Digreen

Understanding Digreen

Digreen is a pharmacological treatment utilized primarily in the management of chronic conditions related to metabolic health. It belongs to a class of medications designed to influence specific physiological pathways that regulate systemic functions.

Primary Mechanism

The therapeutic action of Digreen focuses on stabilizing biochemical processes within the body. By interacting with targeted cellular receptors, it assists in maintaining equilibrium where natural regulatory mechanisms may be insufficient. Its development was centered on providing a consistent physiological response for long-term management strategies.

Clinical Applications

Digreen is typically integrated into a broader management plan. It is utilized for patients who require pharmacological support to address imbalances that have not responded sufficiently to non-medical interventions. The medication is characterized by its specific metabolic profile, which allows for a controlled release and sustained presence within the system.

General Characteristics

  • Therapeutic Intent: Designed for the long-term stabilization of metabolic indicators.
  • Formulation: Developed to ensure predictable absorption and bioavailability.
  • Integration: Often used as a primary component in a comprehensive approach to chronic health maintenance.

In a clinical context, the role of Digreen is to provide a baseline of systemic support, helping to reduce the fluctuations associated with specific chronic health profiles.

Regulatory References

  1. WHO Essential Medicines List for Gliclazide

What side effects are possible with Digreen?

Possible side effects and safety information for Digreen

Official regulatory documents from government health authorities establish the complete safety profile of a medicine. For the medicine named Digreen, the specific adverse reaction data from regulatory sources (such as the FDA, EMA, or Health Canada) is not available to present here.

Regulatory agencies organize safety information into structured domains to communicate risks clearly. If Digreen were an approved medicine, its official safety information would be structured as follows:

Adverse Reaction Grouping

Adverse reactions would be categorized based on their frequency of occurrence in clinical trials, typically using a standard framework (e.g., Very Common, Common, Uncommon). The reactions would also be grouped by the affected body system, known as System-Organ-Classes (e.g., Gastrointestinal Disorders, Nervous System Disorders) to provide a comprehensive view of how the medicine affects the body.

Serious Adverse Reactions and Safety Restrictions

  • Serious Adverse Reactions: The regulatory profile identifies any adverse event that meets predefined criteria for seriousness (e.g., life-threatening, requiring hospitalization) separate from non-serious events, ensuring that the most critical risks are clearly identified.
  • Population-Specific Considerations: The safety profile may contain specific notes related to use in certain patient groups, such as those with severe kidney or liver impairment, or restrictions concerning use during pregnancy or lactation, if those considerations are explicitly documented in the official labeling.
  • Contraindications: This section would list specific medical conditions, patient populations, or co-administered drugs where the medicine must not be used, as formally defined by the regulatory authority to prevent serious harm.

This structured approach to organizing the official safety data ensures that the full range of potential risks, from minor side effects to critical limitations on use, is transparently communicated to establish the authorized risk profile of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Digreen (Gliclazide) is defined by the central risk of profound and sustained hypoglycaemia (low blood sugar), which can be severe and life-threatening. This primary metabolic effect can lead to progressive neuroglycopenia, resulting in serious neurological manifestations documented in regulatory labeling.

Documented Manifestations and Serious Outcomes

Symptoms of overdose, which reflect low blood sugar, include autonomic signs such as sweating, clammy skin, palpitations, and anxiety. More serious neurological signs of neuroglycopenia include confusion, poor concentration, convulsions (seizures), stupor, and potentially coma

. Regulatory documents warn that uncorrected, severe hypoglycemia may result in permanent impairment of brain function or death.

When Immediate Medical Help is Required

Regulatory authorities mandate that immediate medical treatment or hospitalisation are required if a hypoglycaemic episode is classified as severe or prolonged. The initial action, if the patient is conscious, involves the immediate intake of carbohydrates (sugar). However, because hypoglycemia may recur even after initial recovery, prolonged hospital observation for several days may be necessary for all suspected overdose cases, particularly for those with severe hepatic or renal insufficiency and in elderly individuals.

Therapeutic Uses of Digreen

What Digreen Treats: Main Uses and Benefits

Digreen (Gliclazide) is commonly used to help manage symptoms related to systemic imbalance in adults with Type 2 diabetes mellitus, primarily addressing hyperglycemia, or chronically elevated glucose levels. It is applied when management through diet and exercise alone has been insufficient to control blood glucose. It is relevant for easing symptom patterns associated with elevated fasting plasma glucose and may assist with managing postprandial glucose spikes that follow meals. The primary therapeutic benefit supports the management of the chronic vascular stress associated with the condition.


The medication is generally considered relevant when supportive symptom management is appropriate, often introduced as a second-line pharmacological support or may be part of symptomatic management in certain scenarios. It is applied across conditions marked by increased physiological stress, relevant for indications such as controlling Type 2 diabetes, stabilizing long-term glycemic control, and addressing inadequate blood sugar management when HbA1c remains above target. This supportive relief helps maintain a sense of stability when symptoms are more noticeable, offering assistance during phases when symptoms become more disruptive. A key long-term benefit may assist with reducing the risk of developing serious, chronic diabetes-related complications, such as symptoms linked to organ-specific functional stress.


Quick Fact: Relief for Inadequate Blood Sugar Control Digreen is commonly used to help manage the pattern of consistently high HbA1c readings, providing supportive relief when additional symptomatic support for blood sugar stability is needed after lifestyle measures.

Regulatory References

  1. Australian TGA document on DIAMICRON MR

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Digreen (Gliclazide) — Official Regulatory Information

The eligibility for Digreen (Gliclazide) is strictly defined by regulatory authorities for use only in adults (18 years and older) with Type 2 Diabetes Mellitus (T2DM) when diet and exercise alone have proven insufficient. The official regulatory profile establishes clear restrictions and absolute contraindications for other populations.

Contraindicated Populations (Absolute Non-Eligibility)

Digreen is formally contraindicated in several groups and conditions, including:

  • Patients with Type 1 Diabetes Mellitus or acute diabetic crises such as diabetic ketoacidosis.
  • Individuals with known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.
  • Patients with severe hepatic insufficiency or severe renal insufficiency.
  • Women who are pregnant or breastfeeding (lactation).
  • Patients receiving concomitant treatment with systemic miconazole.

Age-Group and Condition Restrictions

Use in children and adolescents is not established and generally not recommended due to insufficient data. While older adults may be eligible, they are officially recognized as a group with an increased risk of hypoglycemia, requiring careful consideration. Eligibility is further restricted by conditions such as galactose intolerance and must be temporarily discontinued during periods of high physiological stress like surgery or severe infection.

What should I know about interactions with other medicines?

Digreen (Gliclazide) has officially documented interaction patterns that modify its blood glucose-lowering effect or affect co-administered substances. The combination of Digreen with Miconazole (systemic or oromucosal gel) is formally contraindicated in regulatory documents.


Documented Drug-Drug Interactions

Interaction profiles classify substances into those that increase the risk of hypoglycemia and those that reduce Digreen’s efficacy, potentially leading to hyperglycemia. Co-administration with other Antidiabetic Agents, NSAIDs, Beta-blockers, or ACE Inhibitors potentiates the blood glucose lowering action. Conversely, substances like Glucocorticoids and Danazol are documented to attenuate the action of Digreen. Digreen also potentiates the effect of Coumarin derivatives, such as Warfarin. In cases where patients are switched from a sulfonylurea with a prolonged half-life, a treatment-free period of a few days may be necessary to avoid overlapping effects that could cause hypoglycemia.


Interactions with Substances and Populations

Regulatory sources require the avoidance of alcohol (Ethanol) as it increases the risk of severe hypoglycemic reactions by inhibiting the body's compensatory mechanisms. The herbal preparation St John's wort is documented to affect blood sugar control and reduce Gliclazide exposure. Furthermore, Digreen is officially contraindicated in patients with severe renal or hepatic insufficiency due to altered processing that heightens the risk of severe, prolonged hypoglycemia. Special caution is noted for elderly patients receiving concomitant Fluoroquinolones due to documented reports of dysglycemia.

Mechanism of Action

The following text describes the mechanism of action of Digreen, detailing only its biological targets, molecular cascades, and resulting physiological modulation.

Dual Targeting of the MAPK and PI3K/AKT Cascades

Digreen functions as a dual-pathway inhibitor, acting on key protein kinases within two fundamental cellular signaling cascades: the mitogen-activated protein kinase (MAPK) pathway and the PI3K/AKT/mTOR cascade (Phosphatidylinositol 3-kinase). The drug's interaction is antagonistic and inhibitory, suppressing the activity of specific kinases in both networks, such as those related to B-Raf or MEK. The simultaneous blocking of these parallel pathways is essential for modulating two central cascades and addressing the potential for pathway crosstalk.

Suppression of Proliferation and Metabolic Signaling

This molecular interference initiates a mechanistic cascade leading to a reduction in the cellular rate of division and metabolic activity. The action modulates the cell's internal command system, shifting its state from high proliferative activity toward a quiescent state. The resulting core physiological change is the suppression of cellular expansion in tissues where these signaling pathways are overactive, influencing the drug's overall effect profile at the tissue level.

Dosage and Administration Information

How Digreen is Used: Official Administration Guidelines

Digreen (Gliclazide Modified-Release) is intended for long-term therapy and is administered exclusively via the oral route as a tablet. The modified-release formulation defines its once-daily usage pattern, which is used according to established protocols.


Standard Adult Dosing and Frequency

Digreen is prescribed for once-daily intake at the time of breakfast, or the first main meal of the day.

Dosing Parameter Gliclazide Modified-Release (MR) Regimen
Initial Daily Dose 30 mg
Maintenance Range 30 mg to 120 mg once daily
Maximum Daily Dose 120 mg

Dose adjustments are made in 30 mg steps and are performed with caution. A period of at least one month is typically observed between dose increments to assess the full metabolic response.


Administration Requirements and Special Populations

To preserve the controlled-release properties of the tablet, the medication must be swallowed whole and should not be crushed or chewed. The intake is accompanied by food to minimize the risk of hypoglycemia. If a dose is forgotten, the standard procedure is to skip the missed dose and resume the normal schedule the following day, rather than doubling the intake.

For older adults, the starting dose remains the minimum 30 mg daily dose. Digreen is not recommended for children and adolescents due to a lack of established safety and efficacy data.

Recent Clinical Evidence

Research evidence / Overview of Studies for Digreen (Gliclazide)

Evidence for use in Long-Term Glycemic Control

Research has explored the relationship between Gliclazide and measurements of high blood sugar levels over time in adults with Type 2 diabetes. Studies in this area primarily rely on Randomized Controlled Trials (RCTs) and systematic reviews. These studies focus on measuring objective blood markers that reflect how sugar levels have been observed, such as Glycated Hemoglobin ( HbA1c), as well as checking Fasting Plasma Glucose (FPG) and glucose levels after meals.

Studies monitored changes measured in HbA1c and other glucose values across the observed populations. Research explored the administration of Gliclazide both as a single therapy and when added to other existing antidiabetic medications. These research results apply to adults with T2DM and contribute to the overall evidence base for managing blood glucose.

Evidence for use in Reducing Microvascular Complications

Large-scale, extended-duration clinical trials, notably the ADVANCE trial, was evaluated in settings of intensive blood sugar control using a regimen that frequently included Gliclazide. This research specifically examined the development or progression of kidney and eye functional stress in the context of intensive glucose management regimens, which included Gliclazide.

Reports described the observed patterns related to combined microvascular complications in the intensive glucose control group compared to standard glucose control over the median five-year follow-up period. Observed patterns related to specific measurements of kidney functional stress were described in this research. While the evidence explored patterns related to microvascular outcomes, a consistent pattern was not reported for major heart- or stroke-related events (macrovascular complications) within the study period.

Research Gaps and Limitations in the Evidence Record

Key limitations in the research record include:

  • Comparative Evidence: Limited information is available from studies comparing all long-term clinical outcomes between Gliclazide and every other sulfonylurea agent across the full range of potential complications.
  • Subgroup Data: Data for certain groups, such as those with severe or worsening kidney functional stress, remain insufficient from large, dedicated clinical trials, meaning results apply only to the populations studied and subgroup findings are uncertain.

Key Studies & References

  1. Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: A Review of the Clinical Effectiveness and Safety – An Update - NCBI Bookshelf
  2. Sulfonylureas - StatPearls - NCBI Bookshelf
  3. Gliclazide Product Monograph (Health Canada Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Digreen (FAQ)


Q: Why is Digreen only available by prescription?

Digreen is classified as a prescription-only medicine because its use requires the oversight of a healthcare professional. This is necessary for the monitoring of blood sugar levels and the management of the known risk of developing hypoglycemia (low blood sugar). Official guidance states that this is intended to ensure appropriate management of the medicine.

Q: Are the side effects from Digreen serious?

Official documents describe the possibility of serious adverse reactions, with the most frequent serious event identified as hypoglycemia (severely low blood sugar). Official safety information notes the importance of adherence to administration guidelines due to this risk. Any sign of a severe reaction is a factor to be discussed immediately with a health professional.

Q: Does Digreen interact with caffeine or alcohol?

Official information states that the consumption of alcohol (ethanol) should be avoided while using this medicine, as it can significantly increase the risk of severe low blood sugar. Caffeine is not typically documented in the formal interaction sections of the official product information.

Q: Is it safe to use Digreen while taking herbal supplements?

Regulatory documents caution against the use of certain herbal preparations due to the potential for interactions. Specifically, St. John's wort is documented to affect blood sugar control and can reduce the medicine's exposure in the body. All supplements should be disclosed to the prescribing physician for review.

Q: What is the difference between Digreen and the generic version of the medicine?

The active ingredient in Digreen is Gliclazide, which is the generic name for the substance that makes the medicine work. The differences between the brand-name Digreen and generic Gliclazide are typically related to the inactive ingredients, the product's appearance, and the manufacturing company, all of which are detailed in the official labeling.

Q: Can Digreen be used by women who are planning to become pregnant?

Official regulatory text states that Digreen is contraindicated (must not be used) during both pregnancy and breastfeeding. The prescribing information describes that the physician is responsible for changing a patient’s blood sugar management treatment when pregnancy is either planned or confirmed.

Q: How quickly can I expect Digreen to start working?

Studies indicate that the initial glucose-lowering action of the medicine begins shortly after administration. However, the full, stable therapeutic benefit is assessed over a period of weeks to months. This full response is determined by measuring stable blood markers like Glycated Hemoglobin ( Hb1c).

Q: What happens if I suddenly stop taking Digreen?

Stopping this medicine suddenly without consulting a healthcare professional is likely to result in the return or worsening of the primary condition, which is hyperglycemia (high blood sugar). The medicine's adherence should be managed as directed to avoid poor control of blood glucose levels.

Q: What are the most commonly reported side effects of Digreen?

According to official documents, the most commonly reported adverse event is hypoglycemia, which is low blood sugar. Other frequently documented reactions involve the gastrointestinal system, though the medicine's full safety profile contains an extensive list of potential effects.

Q: Does Digreen cause stomach issues like nausea or indigestion?

Official safety information documents that gastrointestinal disorders are among the reported side effects. These reactions can include issues such as nausea, indigestion, or abdominal pain, as detailed in the regulatory safety profile.

Q: Has Digreen been associated with changes in sleep patterns?

Official safety documents list potential nervous system effects, such as headache or dizziness. Specific changes to sleep patterns, like insomnia or vivid dreams, are not consistently noted but are covered under the potential for central nervous system-related events.

Q: What are the signs of an allergic reaction to Digreen?

Signs of a hypersensitivity (allergic) reaction, as noted in the safety documentation, may include skin rashes or itching (pruritus). More severe adverse reactions, such as blistering or systemic effects, are also reported and are factors that require immediate attention from a health professional.

Q: Can Digreen affect my blood pressure or heart rate?

Cardiovascular effects are not considered primary features of the medicine’s action. However, official safety data has documented potential for mild changes in some blood markers. Regulatory warnings for the entire sulfonylurea drug class, to which Digreen belongs, address the observed risk of cardiovascular mortality.

Q: Can Digreen interact with medicines used for anxiety or depression?

Interaction profiles list substances that can affect blood sugar control. Medicines that influence blood sugar levels or liver enzyme activity, which may include some agents for mood disorders, are factors that require review by a health professional for potential additive effects.

Q: Will Digreen interfere with getting certain lab tests done?

Digreen is known to significantly affect the results of certain laboratory tests, primarily those measuring blood glucose and Hb1c, as this is its intended effect. Official safety information also suggests it may affect liver enzyme tests due to the potential for rare hepatic reactions.

Q: Is it normal to feel tired when first starting Digreen?

Official safety documents state that fatigue or feeling tired is a reported symptom. This may be a non-specific adverse effect of the medicine or a sign of hypoglycemia (low blood sugar), and is a factor that requires discussion with a health professional.

Q: Does Digreen affect energy levels or focus?

The common side effect of hypoglycemia (low blood sugar) is documented to include symptoms that affect energy and focus. These symptoms can include confusion, difficulty concentrating, or feelings of weakness.

Q: Is there a different name for the condition Digreen treats?

Digreen is used to manage Type 2 Diabetes Mellitus (T2DM). The condition is also sometimes referred to by other common names, such as adult-onset diabetes or non-insulin-dependent diabetes.

Q: What is the typical timeframe before a doctor might change treatment if Digreen isn't working?

Regulatory guidance for managing the medicine suggests waiting a minimum of one month between dose changes to accurately assess the full metabolic response. Decisions to change to a different kind of therapy are based on this clinical assessment of blood glucose control over time.

Q: Are there specific symptoms that get worse if I stop Digreen?

If the medicine is discontinued, the symptoms associated with high blood sugar (hyperglycemia) are expected to return or worsen. These may include excessive thirst, frequent urination, or blurred vision.

Q: How often do people need to have check-ups while on Digreen?

Official regulatory documents recommend regular clinical and laboratory monitoring while using this medicine. This typically involves checking blood sugar and Hb1c levels, with the exact frequency determined by the prescribing physician based on individual needs.

Q: Can Digreen cause changes in mood?

Regulatory documents list psychiatric disorders as potential adverse events. Additionally, symptoms of low blood sugar (hypoglycemia) are documented to sometimes include feelings of emotional instability or irritability.

Q: Does taking Digreen cause weight gain or loss?

Official safety information commonly lists the potential for weight gain as a non-serious side effect for medicines belonging to the sulfonylurea pharmacological class.

Q: What happens in the body when Digreen breaks down?

Regulatory documents on pharmacokinetics describe that the active ingredient is primarily metabolized (broken down) by the liver, specifically by the CYP2C9 enzyme. The resulting inactive substances are then mostly eliminated from the body via the kidneys.

Q: Is it possible to become dependent on Digreen?

Digreen is not associated with the development of physical dependence or addiction in the same way as narcotics. However, patients with Type 2 Diabetes are dependent on this medicine for the ongoing management and control of their blood glucose levels.

Q: Do I need to carry an ID card or bracelet if I am taking Digreen?

Official safety information recommends that patients using blood glucose-lowering agents carry readily available sugars and identification. This information should identify their diabetes condition and the medication they are taking in case of a low blood sugar emergency.

Q: Is there a maximum amount of time Digreen can be prescribed for?

Digreen is indicated for the long-term management of chronic conditions like Type 2 Diabetes Mellitus. There is no maximum duration specified in official documents, provided the patient continues to derive benefit from the treatment.

Q: Why do certain regulatory bodies issue warnings about Digreen?

Regulatory documents include Boxed Warnings (the strongest type of warning) to highlight potential serious risks. For the sulfonylurea class, these warnings specifically relate to the observed association with an increased risk of cardiovascular mortality.

Q: Can Digreen make my skin more sensitive to the sun?

Yes, official safety information has documented the potential for phototoxicity reactions. This means that the medicine may increase the skin’s sensitivity to sun exposure, and individuals should be aware of this potential.

Q: What if I experience unusual dreams while taking Digreen?

Unusual dreams are not consistently noted in documentation but are covered under the potential for central nervous system-related adverse events. Any new or unusual symptom is a factor that requires discussion with a health professional.

Q: How long does it take for Digreen to be completely out of my system?

Regulatory documents on pharmacokinetics state that the half-life of Gliclazide is approximately 12 to 20 hours. Complete elimination of a substance from the body typically takes several of these half-life cycles.

How should Digreen be stored and disposed of?

The storage and disposal of Digreen (Gliclazide Modified-Release) must strictly adhere to the conditions outlined in official regulatory documents to maintain product quality and public safety.

Storage Requirements

The required storage temperature is not exceeding 30 C (86 F), with some regions specifying storage below 25 C. The tablets must be protected from light and moisture and should be kept in the original package until immediately before use. A universal regulatory requirement is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Official guidelines state that unused or expired Digreen must not be thrown away via wastewater or household waste. Disposal must be carried out in accordance with local requirements. The official process is to return the product to a pharmacy or an authorized community drug take-back program for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Digreen found in:

A-Z Index: